PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy
Abstract
Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkpoints have shown promise in promoting anti-tumor immunity. PSGL-1, primarily known for its role in cellular migration, has also been shown to function as a negative regulator of CD4+T cells in numerous disease settings including cancer. PSGL-1 is highly expressed on T cells and can engage numerous ligands that impact signaling pathways, which may modulate CD4+T cell differentiation and function. PSGL-1 engagement in the tumor microenvironment may promote CD4+T cell exhaustion pathways that favor tumor growth. Here we highlight that blocking the PSGL-1 pathway on CD4+T cells may represent a new cancer therapy approach to eradicate tumors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 23, 2021
- Source ID
- 10.3389/fimmu.2021.636238
Entities
People
- Emily N. Neubert
- Julia M. Derogatis
- Karla M. Viramontes
- Roberto Tinoco
Organizations
- Melanoma Research Alliance
- National Institutes of Health
- United States Department of Defense